| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3273 |
| Trial ID | NCT05651100 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Kecellitics Biotech Company Ltd |
| Other ID(s) | Kece-4 |
| Cohort 1 | |||||||||
|
|||||||||